Effect of psychotropics on the risk of COVID-19 in middle-aged and older adults
(2023) In European Neuropsychopharmacology 66. p.67-77- Abstract
Older adults have been markedly impacted by the coronavirus disease 19 (COVID-19) pandemic, and many reports have cited concerns regarding potential psychiatric sequelae of coronavirus disease (COVID-19), but the actual effects of psychotropics on the COVID-19 are unclear. In this study, multivariate logistic regression was used to evaluate associations between the prescription of psychotropics and the risk of SARS-CoV-2 infection, and COVID-19-related death among the participants who were tested for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) before October 18, 2021, in UK Biobank. The psychotropics included 18 types of medications. Among 168,173 participants who underwent testing for SARS-CoV-2 RNA, 30,577 (18.2%)... (More)
Older adults have been markedly impacted by the coronavirus disease 19 (COVID-19) pandemic, and many reports have cited concerns regarding potential psychiatric sequelae of coronavirus disease (COVID-19), but the actual effects of psychotropics on the COVID-19 are unclear. In this study, multivariate logistic regression was used to evaluate associations between the prescription of psychotropics and the risk of SARS-CoV-2 infection, and COVID-19-related death among the participants who were tested for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) before October 18, 2021, in UK Biobank. The psychotropics included 18 types of medications. Among 168,173 participants who underwent testing for SARS-CoV-2 RNA, 30,577 (18.2%) were positive, and 14,284 (8.5%) participants used psychotropics. Among 30,577 participants who were infected with SARS-CoV-2, 1,181 (3.9%) were COVID-19-related deaths, and 2,542 (8.3%) participants used psychotropics. In multivariate logistic regression, psychotropics use was significantly associated with the risk of SARS-CoV-2 infection (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.88–0.98), and COVID-19-related death (OR, 0.78; 95% CI, 0.64–0.98). Interestingly, the use of diazepam was significantly associated with a 31% lower risk of SARS-CoV-2 infection (OR, 0.69; 95% CI, 0.53–0.88). The use of sertraline was significantly associated with a 89% lower risk of COVID-19-related death (OR, 0.11; 95% CI, 0.02–0.39). In conclusion, our findings suggested that the use of psychotropics was associated with a lower risk of SARS-CoV-2 infection and COVID-19-related deaths.
(Less)
- author
- Ma, Yue ; Li, Shu ; Yang, Hongxi ; Zhang, Yuan ; Li, Huiping LU ; Xu, Fusheng ; Hou, Yabing ; Zhang, Xinyu and Wang, Yaogang
- organization
- publishing date
- 2023-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- COVID-19, Pharmacoepidemiology, Psychotropics
- in
- European Neuropsychopharmacology
- volume
- 66
- pages
- 11 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:36463771
- scopus:85143171478
- ISSN
- 0924-977X
- DOI
- 10.1016/j.euroneuro.2022.11.009
- language
- English
- LU publication?
- yes
- id
- 5404496e-efa4-40b0-ac48-8e67749ac20b
- date added to LUP
- 2023-02-07 15:32:55
- date last changed
- 2024-06-13 23:49:04
@article{5404496e-efa4-40b0-ac48-8e67749ac20b,
abstract = {{<p>Older adults have been markedly impacted by the coronavirus disease 19 (COVID-19) pandemic, and many reports have cited concerns regarding potential psychiatric sequelae of coronavirus disease (COVID-19), but the actual effects of psychotropics on the COVID-19 are unclear. In this study, multivariate logistic regression was used to evaluate associations between the prescription of psychotropics and the risk of SARS-CoV-2 infection, and COVID-19-related death among the participants who were tested for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) before October 18, 2021, in UK Biobank. The psychotropics included 18 types of medications. Among 168,173 participants who underwent testing for SARS-CoV-2 RNA, 30,577 (18.2%) were positive, and 14,284 (8.5%) participants used psychotropics. Among 30,577 participants who were infected with SARS-CoV-2, 1,181 (3.9%) were COVID-19-related deaths, and 2,542 (8.3%) participants used psychotropics. In multivariate logistic regression, psychotropics use was significantly associated with the risk of SARS-CoV-2 infection (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.88–0.98), and COVID-19-related death (OR, 0.78; 95% CI, 0.64–0.98). Interestingly, the use of diazepam was significantly associated with a 31% lower risk of SARS-CoV-2 infection (OR, 0.69; 95% CI, 0.53–0.88). The use of sertraline was significantly associated with a 89% lower risk of COVID-19-related death (OR, 0.11; 95% CI, 0.02–0.39). In conclusion, our findings suggested that the use of psychotropics was associated with a lower risk of SARS-CoV-2 infection and COVID-19-related deaths.</p>}},
author = {{Ma, Yue and Li, Shu and Yang, Hongxi and Zhang, Yuan and Li, Huiping and Xu, Fusheng and Hou, Yabing and Zhang, Xinyu and Wang, Yaogang}},
issn = {{0924-977X}},
keywords = {{COVID-19; Pharmacoepidemiology; Psychotropics}},
language = {{eng}},
pages = {{67--77}},
publisher = {{Elsevier}},
series = {{European Neuropsychopharmacology}},
title = {{Effect of psychotropics on the risk of COVID-19 in middle-aged and older adults}},
url = {{http://dx.doi.org/10.1016/j.euroneuro.2022.11.009}},
doi = {{10.1016/j.euroneuro.2022.11.009}},
volume = {{66}},
year = {{2023}},
}